BioAlliance Pharma : Disclosure of total number of voting rights and number of shares in the capital at September 30, 2012
October 05 2012 - 12:05PM
Business Wire
Regulatory News:
BioAlliance Pharma (Paris:BIO) :
Pursuant to article L.233-8 II of the Code
de commerce (the French Commercial Code) and article 223-16 of
the Règlement général de l’Autorité des Marchés Financiers
(Regulation of the French stock market authority):
Date Total number of outstanding shares Total number
of voting rights September 30, 2012 17,659,715
Theoretical number of voting rights: 17,659,715(including treasury
shares)
Number of real voting rights:
17,631,926(without treasury shares)
About BioAlliance Pharma
Dedicated to Specialty Pharma and Orphan products in cancer
treatment and in supportive care, with a focus on drug resistance,
BioAlliance conceives and develops innovative products, for
specialty markets especially in the hospital setting and for orphan
or rare diseases.
Created in 1997 and introduced to the Euronext Paris market in
2005, BioAlliance Pharma’s ambition is to become a leading player
in these fields by coupling innovation to patient needs. The
company’s teams have the key competencies required to identify,
develop and register drugs in Europe and USA; the products’
commercialization rights are licensed to international commercial
partners invested in the hospital setting. In areas where medical
needs are insufficiently met, its targeted approaches help overcome
drug resistance and improve patient health & quality of life.
For more information, visit the BioAlliance Pharma web site at
www.bioalliancepharma.com.
Biotest (TG:BIO)
Historical Stock Chart
From Sep 2024 to Oct 2024
Biotest (TG:BIO)
Historical Stock Chart
From Oct 2023 to Oct 2024